AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06609486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement group
Description: In this study, the protocol applied to automatic electronic blood pressure system module BN1 for performance evaluation is ISO's proposed ISO 81060-2:2018 Non-invasive sphygmomanometers- Part2: Clinical investment of internal automatic measurement type. The initial BP measurement is performed alternately, measuring the blood pressure by the measurer and the test device once each, and measuring blood pressure by the measurer four times by the observer and three times by the test device.
Study NCT01683604 — intervention group
Intervention type: OTHER
Intervention: Observational study
Study NCT01466738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HRV-16 (100 TCID50)
Description: Each volunteer will receive a single administration of 100 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
Study NCT01466738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HRV-16 (1000 TCID50)
Description: Each volunteer will receive a single administration of 1000 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
Study NCT02440061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic human AG
Description: Synthetic human AG (0.28 μg/kg) bolus over 1 minute followed by 2 μg/kg/hr continuous infusion for 4.5 hours.
Study NCT02440061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: Arginine hydrochloride (5 g) intravenously over 45 seconds.
Study NCT02440061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline solution
Description: A continuous infusion of 0.9% saline solution (control) for 4.5 hours.
Study NCT02025283 — intervention group
Intervention type: PROCEDURE
Intervention: Group Decompression or Group Nucleoplasty
Description: Group Decompression: Decompression with flexible intradiscal decompression catheter (SpineCATH®, Smith \& Nephew, Memphis, TN) Group Nucleoplasty: Nucleoplasty with radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM \[ArthroCare Spine, Sunnyvale, CA\]
Study NCT03127319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib docetaxel zoledronic
Description: apatinib 500 mg qd p.o.docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
Study NCT03127319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel zoledronic
Description: docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
Study NCT02107846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-112
Study NCT03213847 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Superb microvascular imaging (SMI) (Toshiba)
Description: to determine whether there is a correlation between the increased intraneural flow as measured using Doppler US and SMI methods and the severity of CTS as measured by nerve conduction studies, we designed this study
Study NCT02260960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 (Triglyceride form)
Study NCT02260960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 (Triglyceride form)
Study NCT02176369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Capsule soft (20/30 mg) - 50 mg three times a week (monday, wednesday and friday) for a three weeks cycle (then recycled the next week at the same doses)Treatment will be continued until progression, unacceptable toxicity or death.
Study NCT00901043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnut supplementation
Description: Eight weeks of walnut supplementation
Study NCT00901043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ad lib diet
Description: Eight weeks without walnut supplementation
Study NCT04178304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolotherapy with 25% Dextrose
Description: Intra-articular injection of 6mL of 25% dextrose Extra-articular injection at tender sites with 25% dextrose
Study NCT04018495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Tracker
Description: Fitbit tracker; is an activity tracking product that is wireless-enabled wearable technology device that measures data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness
Study NCT00616746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 1.0 microg/kg/min IV x 10 minutes
Study NCT00616746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: IV
Study NCT03000946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: Lyophilisate and solution for IV use (glass ampoule of lyophilisate + 1 ml glass ampoule of solvent) 6 mg per day Continuous intravenous infusion for 6,5 days
Study NCT03000946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Solution for Subcutaneous use 100μg, every 8 hours Subcutaneous injection for 6,5 days
Study NCT04441346 — intervention group
Intervention type: RADIATION
Intervention: Echocardiography
Description: test that uses high frequency sound waves (ultrasound) to make pictures of your heart.
Study NCT00667485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin (liquid)
Description: Weekly Rapamycin (liquid) 90mg (dose will be split 45mg on Day 1 and Day 2 of each week)
Study NCT00667485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks
Study NCT00667485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin (Tablets)
Description: Daily oral rapamycin (tablets) - 2 doses will be tested 4mg and 6mg
Study NCT02632604 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer games
Study NCT02473731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTN3379
Study NCT00541177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atropine
Description: 0.25% atropine
Study NCT00541177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tropicamide
Description: 0.5% tropicamide
Study NCT01791075 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tan Endoglide
Description: Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
Study NCT01791075 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endosaver
Description: Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
Study NCT01008865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Studer Pouch orthotopic urinary diversion
Study NCT01008865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-Pouch orthotopic urinary diversion
Study NCT02917603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Conferencing
Description: Individuals will communicate with the nursing home team via web conferencing during quarterly care conference
Study NCT03449901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated arginine deiminase
Description: -Arginine deiminase (ADI) is a recombinant protein cloned from M. hominis, produced in E. coli, and conjugated with PEG of 20,000 mw using a succinimidyl succinate linker. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
Study NCT03449901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: -Gemcitabine is a nucleoside metabolic inhibitor that exhibits antitumor activity.
Study NCT02319252 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric tube (Nutricia Flocare® Pur Tube Enlock)
Description: Nutricia Flocare® Pur Tube Enlock, Ch. 12
Study NCT02319252 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jejunal tube (Nutricia Flocare® Bengmark®)
Description: Nutricia Flocare® Bengmark®, Ch. 10
Study NCT00523770 — intervention group
Intervention type: PROCEDURE
Intervention: Urine sample collection
Description: Urine samples will be collected and tested for the presence of S. pneumoniae
Study NCT02675764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration
Description: peripheral vibration at the wrist skin at an imperceptible level
Study NCT02675764 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for vibration)
Description: No peripheral vibration at the wrist skin
Study NCT02675764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapy
Description: standardized hand therapy program
Study NCT03449901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: -Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants.
Study NCT03449901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: * Up to 21 days prior to initiation of ADI-PEG 20 Day -1 (+/- 1 day as long as performed prior to initiation of gemcitabine.~* Tumor biopsies are mandatory for the first 20 patients amendable to biopsy enrolled at Washington University only (completed as of 05/14/2019) and for all patients enrolled to the SCLC cohort
Study NCT02675764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: therapy
Description: standardized hand therapy program
Study NCT01707641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CD#2
Description: patient will be asked to take 6 lozenges every day and let it dissolve slowly in the mouth
Study NCT01707641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bicarbonate sodium mouthwash
Description: Patients will be asked to wash their mouth with bicarbonate sodium several times per day
Study NCT01398852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Riboflavin is a solution that will be delivered to the treatment area
Study NCT03449901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Day -7 (pre-treatment), Day -1, and Days 1 and 8 of each cycle
Study NCT01398852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEGA UV-A Illumination System
Description: This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
Study NCT03281746 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Procedure
Description: Undergo dental examination
Study NCT03281746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Procedure
Description: Undergo dental examination
Study NCT03281746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention (prevention education)
Description: Receive prevention education
Study NCT03808818 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral, Psychological or Informational Intervention
Description: Receive information about tobacco cessation
Study NCT03281746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention (prevention education)
Description: Receive prevention education
Study NCT03281746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies
Study NCT03281746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT03281746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03281746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03281746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention (one-on one education)
Description: Receive one-on-one education
Study NCT01082679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methadone
Description: daily for 12 months
Study NCT01082679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: buprenorphine (Suboxone)
Description: daily for 12 months
Study NCT03082027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonography
Description: ultrasonography of median nerve
Study NCT04649879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 convalescent plasma
Description: Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 10 CP infusions. CP will be given as a slow infusion over 2 hours. CP neutralization titre of ≥ 1/640 or an ELISA reactivity against the Spike protein of SARS-CoV-2 by the Euroimmun commercial assay >9 is desired. New antibody tests are under development and can be used instead if equivalence to neutralization or Euroimmun ELISA is demonstrated.
Study NCT04649879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care as determined by hospital practices for COVID-19 patients.
Study NCT02250300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708 (2.3 mg)
Description: 2.3 mg
Study NCT02250300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708 (4.0 mg)
Description: 4.0 mg
Study NCT03808818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Given NRT patch or lozenge (or both)
Study NCT03808818 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02250300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708 (3.0 mg)
Description: 3.0 mg
Study NCT02855775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional blood sample
Description: blood sample every 3 weeks
Study NCT00630799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: 17 mg i.m.
Study NCT01278602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-ESHAP
Description: Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
Study NCT01557673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NG bolus feeding over 5 min
Description: Tube bolus (TB): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., administered via the NG tube over 5 min.
Study NCT01557673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Continuous NG feeding over 4 h
Description: Continuous tube drip feeding (TD): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., delivered via feeding pump through the NG tube over 4 h.
Study NCT00954122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (Seroquel XR)
Description: Tablet, oral, once daily
Study NCT03380871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PV-01
Description: Personal Cancer Vaccine
Study NCT03380871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: monoclonal antibody against PDL1
Study NCT03380871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant
Description: immune adjuvant
Study NCT03380871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: chemotherapy
Study NCT03380871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: chemotherapy
Study NCT02699996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete interview
Study NCT02699996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Complete the self management + peer mentoring intervention with videoconferencing
Study NCT01781208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)
Description: Research scans using ultrasound-based acoustic radiation force impulse (ARFI) will image the liver non-invasively.
Study NCT02898857 — intervention group
Intervention type: OTHER
Intervention: biopsies
Description: The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches in Six with demonstrated down-staging of a KRAS mutant adenocarcinoma, Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma and Six with or without non-staging and triple negative adenocarcinoma
Study NCT01060189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Study NCT01060189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT01060189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Study NCT02019342 — intervention group
Intervention type: OTHER
Intervention: FACE quality improvement initiative (see below)
Description: Feedback (F): Regular feedback to practitioners; MAP Alerts (A): Change in electronic alert systems for high and low mean arterial pressure with patient specific alerts; Checklist (C): Interactive checklist in relation to the quality improvement initiative; Education campaign (E): Education campaigns about best intraoperative management of blood pressure.
Study NCT02019342 — intervention group
Intervention type: OTHER
Intervention: Pre-quality improvement initiative
Description: Patients in the pre-quality improvement initiative arm would receive current standard practice.
Study NCT02073526 — intervention group
Intervention type: DRUG
Intervention: Infliximab, adalimumab, certolizumab pegol
Description: Patients are treated with the above mentioned drugs decided by clinicians
Study NCT01991964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: laryngeal ultrasound
Study NCT01991964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laryngeal ultrasound
Study NCT03151447 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: In patients with metastatic triple negative breast cancer, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1\~5 measurable metastatic lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (JS001) is injected intravenously 120mg or 240mg or 360mg every two weeks.
Study NCT00929994 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cardiac Rehabilitation
Description: Individualized cardiac rehabilitation for 6 months, including health education sessions, as well as supervised exercise classes which include aerobic and resistance training.
Study NCT01808274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards CENTERA Self-Expanding Transcatheter Heart Valve
Description: The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
Study NCT01442012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ear seeds
Description: The investigators will use ear seeds to stimulate acupuncture points. The seeds will be applied when the patients are in the preoperative room. After the patients have been discharged, they will need to stimulate these points every eight hours for five minutes, and every time they have nausea and/or vomiting during the first three postoperative days.
Study NCT01442012 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ear seeds
Description: The investigators will use ear seeds to stimulate acupuncture points. The seeds will be applied when the patients are in the preoperative room. After the patients have been discharged, they will need to stimulate these points every eight hours for five minutes, and every time they have nausea and/or vomiting during the first three postoperative days.
Study NCT03808818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03808818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03808818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive virtual tobacco cessation counseling
Study NCT01343862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: single dose of D-cycloserine given 48-72 hours after moderate traumatic brain injury
Study NCT01343862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A sugar pill will be given to those patients randomized to the control group at 48-72 hours after moderate brain injury
Study NCT01506973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Study NCT01506973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT01506973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane